cas 2340116-84-7|| where to buy 1-(3-Chloro-5-fluoro-2-((4-methoxyphenoxy)methyl)phenyl)ethanone

Produktname:1-(3-Chloro-5-fluoro-2-((4-methoxyphenoxy)methyl)phenyl)ethanone

IUPAC Name:1-{3-chloro-5-fluoro-2-[(4-methoxyphenoxy)methyl]phenyl}ethan-1-one

: CAS：2340116-84-7; Molekulare Formel：C16H14ClFO3; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2340116-84-7 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2340116-84-7; Molekulare Formel:C16H14ClFO3; Schmelzpunkt:-; SMILES-Code:O=C(C=1C=C(F)C=C(Cl)C1COC2=CC=C(OC)C=C2)C; Dichte:

: Katalognummer:CM1075077; Molekulargewicht:308.73; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Deucrictibant; Pharvaris announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful results of deucrictibant as an oral preventative treatment for people living with HAE. The study's primary endpoint measured the time-standardized number of investigator-confirmed HAE episodes during treatment. Participants receiving 40 mg of deucrictibant daily had an 84.5% reduction in monthly exacerbation rates compared to placebo (p=0.0008). Deucrictibant is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. By inhibiting bradykinin signaling through the bradykinin B2 receptor, deucrictibant has the potential to treat the clinical signs of an HAE attack and to prevent the occurrence of attacks.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.